A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

Phase 1 Recruiting 16 enrolled Incyte Corporation

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with severe renal impairment or end stage renal disease.

Timeline

Start: 2026-05-29
Primary completion: 2027-01-04
Completion: 2027-01-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INCB123667	Unknown	—	Oral

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

Summary

Timeline

Drugs

Indications